直接口服抗凝药与中高危心房颤动患者死亡率的关系
本研究基于Clalit健康服务电子数据库开展回顾性队列研究,纳入2011至2016年新诊断、未接受过抗凝治疗且适合DOAC的非瓣膜性心房颤动患者。经倾向评分匹配后,DOAC治疗组5657例与非抗凝组5657例相比,全因死亡率显著更低(HR=0.69,95%CI 0.63–0.75,p<0.001)。
要点
- DOAC治疗与中高危NVAF患者全因死亡风险显著降低相关(HR=0.69)。
- DOAC组年死亡率7.6%,非抗凝组11.1%。
- 各亚组分析均显示DOAC治疗获益。
核心结论
- 在新诊断的非瓣膜性心房颤动患者中,DOAC治疗与不进行口服抗凝相比,全因死亡风险显著降低。
- 研究结果为NVAF患者应接受DOAC抗凝提供了进一步证据。
研究设计与样本
- 回顾性队列研究,分析Clalit健康服务电子数据库。
- 主要结局为全因死亡,末次随访日期为2017年5月15日。
主要发现
- DOAC组死亡715例(每年7.6%),非抗凝组死亡2075例(每年11.1%)。
- DOAC治疗与全因死亡风险显著降低相关(HR=0.69,95%CI 0.63至0.75,p<0.001)。
- 所分析的所有亚组中均显示DOAC治疗的获益。
临床怎么用
- 对适合DOAC的新诊断NVAF患者,不应无理由不予抗凝,因DOAC治疗与死亡风险降低相关。
局限性
- 为回顾性队列研究,结果可能受未测量混杂因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Although direct oral anticoagulants (DOAC) are the recommended antithrombotic therapy for patients with non-valvular atrial fibrillation (NVAF), anticoagulation in patients with NVAF is still inadequate. The effect of withholding DOAC therapy on patient survival is unknown. Therefore, our objective was to compare all-cause mortality rates between DOAC-treated patients with NVAF and similar patients receiving no anticoagulation. METHODS: We performed a retrospective cohort study analysing Clalit Health Services' extensive electronic database, regarding all newly diagnosed, anticoagulant-naïve patients with NVAF who were eligible for DOAC therapy from 1 January 2011 to 31 December 2016. Patients who received DOAC therapy were matched by propensity scoring to patients receiving no anticoagulation. The primary outcome was all-cause mortality. Final patient follow-up date was 15 May 2017. RESULTS: 18 901 eligible patients were identified. 8298 received treatment with a DOAC and 10 603 received no anticoagulation therapy. Of those, 5657 patients who received DOAC therapy were matched with 5657 patients who did not receive any anticoagulant. Death occurred in 715 patients in the DOAC-treated group (7.6% per year) and in 2075 patients in the non-anticoagulated patient group (11.1% per year). DOAC therapy was associated with significantly lower risk for all-cause mortality (HR=0.69, 95% CI 0.63 to 0.75, p<0.001). The benefit of DOAC therapy was demonstrated across all subgroups analysed. CONCLUSIONS: In this cohort of newly diagnosed patients with NVAF, DOAC therapy was associated with a significantly lower risk of death compared with no oral anticoagulation. Our findings provide further evidence for the importance of providing DOAC anticoagulation in patients with NVAF.
引用
- Arbel R, Sergienko R, Hammerman A, et al. Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. Heart. 2019. PMID: 30971403. doi:10.1136/heartjnl-2018-314476
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。